|1.||Medicherla, Satyanarayana: 6 articles (01/2010 - 06/2006)|
|2.||Higgins, Linda S: 6 articles (01/2010 - 06/2006)|
|3.||Protter, Andrew A: 5 articles (01/2010 - 05/2007)|
|4.||Kerr, Irene: 3 articles (01/2010 - 11/2008)|
|5.||Ma, Jing Y: 3 articles (01/2009 - 06/2006)|
|6.||Tong, Sandra E: 2 articles (05/2012 - 05/2011)|
|7.||Dugar, Sundeep: 2 articles (01/2009 - 10/2008)|
|8.||Chakravarty, Sarvajit: 2 articles (01/2009 - 10/2008)|
|9.||Navas, Tony A: 2 articles (11/2008 - 06/2006)|
|10.||Reddy, Mamatha: 2 articles (11/2008 - 06/2006)|
10/01/2008 - "Bone erosion and tumor growth were also examined but no significant reduction of bone erosion or tumor growth was observed in the SCIO-469 treated mice. "
11/01/2008 - "A significant dose-dependent reduction in RPMI-8226 tumor growth was also observed when SCIO-469 oral treatment at doses of 10, 30 and 90 mg/kg twice daily was initiated in mice with tumors of pronounced size, a condition that mimics advanced human myeloma disease. "
11/01/2008 - "In mice with palpable tumors, 14 days of SCIO-469 treatment significantly reduced RPMI-8226 tumor growth in a dose-dependent manner. "
11/01/2008 - "Oral treatment with SCIO-469 (10, 30, 90 mg/kg) twice daily was initiated in mice with palpable tumors of RPMI-8226 origin, a condition that mimics early human myeloma disease. "
05/15/2007 - "Treatment of C57Bl/KaLwRij mice bearing 5T33MM cells with SCIO-469 inhibited p38alpha MAPK phosphorylation and was associated with a significant decrease in serum paraprotein, an almost complete reduction in tumor cells in the bone marrow, a decrease in angiogenesis, and a significant increase in disease-free survival. "
11/01/2004 - "By July 2004, SCIO-469 was in phase lib clinical trials for rheumatoid arthritis."
05/01/2011 - "A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis."
05/01/2011 - "To evaluate the efficacy, safety, and tolerability of oral SCIO-469, a p38 MAPK inhibitor that blocks tumor necrosis factor-α, interleukin-1ß, and cyclooxygenase-2 synthesis in patients with active rheumatoid arthritis (RA). "
05/01/2012 - "This prospective, double-blind, randomized clinical study compared efficacy and safety of oral SCIO-469, ibuprofen, and placebo in postsurgical dental pain. "
05/01/2012 - "SCIO-469 is a selective p38α mitogen-activated protein kinase (MAPK) inhibitor for preclinical models of acute pain. "
03/01/2009 - "To assess the potential use of p38 kinase inhibition as a therapeutic strategy to manage fracture pain, the analgesic properties of SCIO-469, a p38alpha kinase inhibitor, were assessed in a rat fracture model and compared to other common analgesics. "
|4.||Myelodysplastic Syndromes (Myelodysplastic Syndrome)
|1.||Protein Kinases (Protein Kinase)
|2.||indole-5-carboxamide (SD 282)
|4.||p38 Mitogen-Activated Protein Kinases
|5.||Cyclooxygenase 2 (Cyclooxygenase-2)
|6.||Fibroblast Growth Factor 7
|7.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|8.||Brain Natriuretic Peptide (Natrecor)
|2.||Heterologous Transplantation (Xenotransplantation)